Literature DB >> 1622184

Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams.

M Dan1, T Zuabi, C Quassem, H H Rotmensch.   

Abstract

The penetration of ciprofloxacin into the ascitic fluid of eight patients was studied. Serum and ascitic fluid samples were obtained before and at 1, 2, 3, 6, and 12 h following administration of a single oral dose of 750 mg. Peak levels (mean +/- standard deviation) were 4.0 +/- 0.7 micrograms/ml in serum and 2.6 +/- 0.6 micrograms/ml in ascitic fluid; the areas under the curve (0 to 12 h) were 29.1 +/- 6.5 micrograms.h/ml in serum and 20.7 +/- 5.0 micrograms.h/ml in ascitic fluid. The concentrations that were achieved are well above the MICs of ciprofloxacin for the members of the family Enterobacteriaceae that cause spontaneous bacterial peritonitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622184      PMCID: PMC190579          DOI: 10.1128/AAC.36.3.677

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Fluoroquinolone antimicrobial agents.

Authors:  D C Hooper; J S Wolfson
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

2.  Intraperitoneal penetration of ciprofloxacin.

Authors:  M R Lockley; R Waldron; R Wise; I A Donovan
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients.

Authors:  D R Guay; W M Awni; P K Peterson; S Obaid; R Breitenbucher; G R Matzke
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

4.  Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis.

Authors:  M P Weinstein; P B Iannini; C W Stratton; T C Eickhoff
Journal:  Am J Med       Date:  1978-04       Impact factor: 4.965

Review 5.  Spontaneous bacterial peritonitis. A review of pathogenesis, diagnosis, and treatment.

Authors:  C M Wilcox; W E Dismukes
Journal:  Medicine (Baltimore)       Date:  1987-11       Impact factor: 1.889

Review 6.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  6 in total
  4 in total

1.  Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.

Authors:  S de Marie; M F VandenBergh; S L Buijk; H A Bruining; A van Vliet; J A Kluytmans; J W Mouton
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 2.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

3.  Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.

Authors:  J S Solomkin; H H Reinhart; E P Dellinger; J M Bohnen; O D Rotstein; S B Vogel; H H Simms; C S Hill; H S Bjornson; D C Haverstock; H O Coulter; R M Echols
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

Review 4.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.